|
Market Closed -
Nasdaq
02:30:00 13/11/2026 am IST
|
5-day change | 1st Jan Change | ||
| 0.8270 USD | -8.12% |
|
-24.13% | -39.64% |
| 10/11 | Allogene Therapeutics, Inc. - Special Call | |
| 09/11 | Allogene Therapeutics Reports First Clinical Data From Phase 1 RESOLUTION Study Of ALLO-329 In Autoimmune Disease | CI |
| Market Cap | 29Cr 26Cr 24Cr 22Cr 41Cr 2.69TCr 42Cr 287.08Cr 114.08Cr 1.44TCr 107.54Cr 105.24Cr 4.58TCr | P/E 2026 * |
-1.37x | P/E 2027 * | -1.28x |
|---|---|---|---|---|---|
| Enterprise Value | 4.44Cr 4.02Cr 3.71Cr 3.36Cr 6.34Cr 417.79Cr 6.53Cr 45Cr 18Cr 223.35Cr 17Cr 16Cr 710.93Cr | EV / Sales 2026 * |
10.7x | EV / Sales 2027 * | 12.3x |
| Free-Float |
89.01% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ALLO | Delayed | |
CBOE
| ALLO | Real-time |
Last Transcript: Allogene Therapeutics, Inc.
| 1 day | -8.12% | ||
| 1 week | -24.13% | ||
| Current month | -29.92% | ||
| 1 month | -40.93% | ||
| 3 months | -60.05% | ||
| 6 months | -64.04% | ||
| Current year | -39.64% |
| 1 week | 0.82 |  | 1.1 |
| 1 month | 0.82 | | 1.38 |
| Current year | 0.82 | | 4.46 |
| 1 year | 0.82 | | 4.46 |
| 3 years | 0.82 | | 5.78 |
| 5 years | 0.82 | | 19.52 |
| 10 years | 0.82 | | 55 |
| Manager | Title | Age | Since |
|---|---|---|---|
Zachary Roberts
CEO | Chief Executive Officer | 48 | 01/07/2026 |
Benjamin Beneski
CTO | Chief Tech/Sci/R&D Officer | 49 | 28/02/2025 |
Earl Douglas
CMP | Compliance Officer | 63 | 14/08/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Arie Belldegrun
CHM | Chairman | 76 | 01/11/2017 |
David Chang
BRD | Director/Board Member | 66 | 01/06/2018 |
Joshua Kazam
BRD | Director/Board Member | 49 | 01/11/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 21/10/26 | Sell | Chief Financial Officer | -36,342 | 0.0105% | ||
| 21/08/26 | Sell | Compliance Officer | -29,697 | 0.0086% | ||
| 01/07/26 | Free | Chief Executive Officer | 6,10,720 | 0.1769% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 41.62L 37.64L 34.74L 31.45L 59.34L 39Cr 61.12L 4.17Cr 1.66Cr 21Cr 1.56Cr 1.53Cr 67Cr | 1.17Cr 1.06Cr 97.46L 88.22L 1.66Cr 109.76Cr 1.71Cr 12Cr 4.65Cr 59Cr 4.38Cr 4.29Cr 186.78Cr |
| Net income | -19Cr -17Cr -16Cr -14Cr -27Cr -1.8TCr -28Cr -192.1Cr -76Cr -963.6Cr -72Cr -70Cr -3.07TCr | -23Cr -21Cr -19Cr -18Cr -33Cr -2.18TCr -34Cr -232.34Cr -92Cr -1.17TCr -87Cr -85Cr -3.71TCr |
| Net Debt | -24Cr -22Cr -20Cr -18Cr -35Cr -2.28TCr -36Cr -242.55Cr -96Cr -1.22TCr -91Cr -89Cr -3.87TCr | -14Cr -13Cr -12Cr -11Cr -20Cr -1.34TCr -21Cr -143.18Cr -57Cr -718.19Cr -54Cr -52Cr -2.29TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/26/12 | $0.8270 | -8.12% | 1,06,87,592 |
| 11/26/11 | $0.9001 | -3.41% | 1,53,69,383 |
| 10/26/10 | $0.9319 | -12.08% | 2,28,65,240 |
| 09/26/09 | $1.060 | +1.92% | 1,07,68,824 |
| 06/26/06 | $1.040 | -4.59% | 1,26,25,093 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- ALLO Stock
Select your edition
All financial news and data tailored to specific country editions
